Loading
A phase 1/2 trial of IPN01195 in advanced solid tumours, run by Ipsen, now recruiting.
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours is a phase 1/2 interventional study registered as NCT06833008 by Ipsen, with 85 participants planned, started 2025-03-14 and due to reach its primary completion in 2028-10-03. Interventions recorded: IPN01195.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Ipsen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipsen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Ipsen, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/